tailieunhanh - An Australian translational Study to evaluate the prognostic role of inflammatory markers in patients with metastatic ColorEctal caNcer Treated with bevacizumab (Avastin™) [ASCENT]

The use of bevacizumab in combination with fluoropyrimidine-containing chemotherapy is a wellestablished first-line and second-line treatment for patients with metastatic colorectal cancer (mCRC). However, there remains a need for reproducible, validated, inexpensive and accessible prognostic markers to aid treatment selection. |

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN